Servier and Vernalis extend cancer collaboration
This article was originally published in Scrip
Executive Summary
Vernalis and Servier have extended an existing collaboration signed three years ago under which they are using Vernalis's fragment and structure-based drug discovery platform to identify potential development candidates for cancer.